Cell Stress & Immunity (CSI) Lab
@AbhishekDGarg
Followers
678
Following
4K
Media
161
Statuses
3K
CSI Lab @KU_Leuven (head: Prof Abhishek Garg) uses novel reverse translation powered by #multiomics #AI to solve #cancer #immunology & #immunotherapy mysteries!
Louvain, Belgium
Joined July 2020
📢Happy to share our @NatRevImmunol article; Result of excellent #collaboration with @deadoc80 @AdrianListon & K Smith! 📑Read here: https://t.co/xKGBrzWdgr 🔥Take🏠msg: Time to move away from narrow concept of #exhausted T cells to other #states! 1/6🧵 @OncoDailyIO @oncodaily
3
11
49
💥 #Cool #Research #Alert
#Spatiotemporal #transcriptomic insights into #ferroptosis and TFRC-linked #immune #interactions in #ischemia-#reperfusion acute #kidney #injury
#Genes & #Immunity @SpringerNature
https://t.co/ypi9khNucu
nature.com
Genes & Immunity - Spatiotemporal transcriptomic insights into ferroptosis and TFRC-linked immune interactions in ischemia-reperfusion acute kidney injury
0
0
0
💥👁 #Exciting #research #alert
#Macrophage #retrotransposon expression is associated with #lupus
#genes & #Immunity @SpringerNature
https://t.co/Dq1MjmfyIj
0
0
2
💥 #YTHDF1 mediates #KLF2/ #VSIG4 axis to regulate #Kupffer #cell #polarization to alleviate #sepsis-induced #liver #injury
#genes & #Immunity @SpringerNature
https://t.co/QuiXct0z16
nature.com
Genes & Immunity - YTHDF1 mediates KLF2/VSIG4 axis to regulate Kupffer cell polarization to alleviate sepsis-induced liver injury
0
1
1
🚨 Effects of #nucleic #acid #metabolism on #prognosis and #immune #invasion of triple-negative #breast #cancer
#genes & #Immunity @SpringerNature
nature.com
Genes & Immunity - Effects of nucleic acid metabolism on prognosis and immune invasion of triple-negative breast cancer
0
0
1
Dr. Jianghong Zhong and colleagues at @Beihang1952 show that MTD retrotransposons play a crucial role in driving the early onset of #lupus by enhancing macrophage activation, which in turn promotes #ImmuneDysregulation. 🤩 Check it out: https://t.co/go803rx9Gz
0
2
4
Very proud and happy to share that our work on neoadjuvant IO in pMMR colon cancers has been published online in @Nature after presentation @myESMO #ESMO25. Preview: https://t.co/KR6mBytwV3 Read on how genomic instability, P53mt and proliferation may aid in predicting responses.
22
120
502
STELLAR-303 lights up the refractory CRC space 🌌🧬 @OncoAlert For the first time, an IO-based regimen shows an OS benefit in microsatellite-stable (MSS) metastatic CRC — a setting long resistant to immunotherapy. STELLAR-303 compared zanzalintinib + atezolizumab vs
thelancet.com
STELLAR-303 is the first phase 3 trial to show a significant improvement in overall survival with an immunotherapy-based regimen, zanzalintinib–atezolizumab, in patients with relapsed or refractory...
3
26
51
🚨 #ESMO25 #LiverCancer – Phase III TALENTop trial: Atezolizumab + Bevacizumab ± surgery in HCC with macrovascular invasion 🎯 mTTF 20.4 vs 11.8 mo | HR 0.59 (95% CI 0.39–0.89, p=0.011) 💥 OS trend HR 0.67 (95% CI 0.35–1.29, immature) 👍🏼 Surgery feasible, grade ≥3 AEs 27.7% (vs
1
13
26
🚫 The phase III PAULIEN trial in 1L PD-L1 ≥50% NSCLC showed no added benefit from combining chemotherapy with pembrolizumab. No improvement in response, PFS, or OS — just higher toxicity. Sometimes, immunotherapy alone is enough. 💬 Do you think that’s enough for these
0
7
23
🆙#ESMO25🇩🇪 🔥#LCSM Mini Oral, Develop Tx ☑️Iza-Bren (BL-B01D1): Phase I global study of EGFR x HER3 bispecific ADC, in pts with metastatic or unresectable NSCLC and other solid tumors ☑️ EGFR+/- ORR: 30.0%/75% 🎙️ @HelenaYu923
@OncoAlert @myESMO @Larvol @EGFRResisters
1
15
28
#ESMO25 | #UpperGI IMbrave152 / SKYSCRAPER14 No added benefit with tiragolumab (anti-TIGIT) on top of atezolizumab + bevacizumab in 1L advanced #HCC. 📈 mPFS 8.3 vs 8.2 mo (HR 0.97) 🧠 ORR 29.9% vs 26% ⚕️ Toxicity as expected—mainly immune & vascular events @myESMO @OncoAlert
1
11
26
🎯 HARMONi-6 delivers new hope in 1L advanced squamous #NSCLC 🫁 📍 Phase III | n=532 | 1L Stage IIIB–IV sqNSCLC 💊 Arms: 🔹 Ivonescimab + chemo (20 mg/kg Q3W) 🔹 Tislelizumab + chemo (200 mg Q3W) → Followed by monotherapy maintenance 📈 Results: • PFS: 11.1 mo vs 6.9 mo (HR
1
26
58
🚀 The #ESMO25 data keep coming! In 1L sq-NSCLC, the HARMONi-6 trial showed that Ivonescimab + chemo delivered a clear PFS win over Tislelizumab + chemo. 🕒 11.1 vs 6.9 mo (HR 0.60, p<0.0001) Benefit consistent across all PD-L1 subgroups. 🧬 Manageable safety — a promising step
0
6
27
For the first time, a significant overall survival benefit with immunotherapy in platinum-resistant ovarian cancer! #ESMO25 #Immunotherapy #GynOnc #KeynoteB96 #Oncology
@myESMO @OncLive @CParkMD @tugbawitter @Dr_ElvinaA @atakansare2016 @drmukremin @dr_yakupergun @OncoAlert
0
29
57
What an absolute pity! #cancer #vaccines #melanoma
#ESMO25: BioNTech stops further work on cancer vaccine in advanced melanoma -
endpoints.news
BioNTech is not moving forward with a cancer vaccine for late-stage melanoma, a spokesperson for the company told Endpoints News.
0
0
0